Lexington-based biotech firm, Frequency Therapeutics, Inc. is leveraging its innovative Progenitor Cell Activation approach to develop cutting-edge therapeutics that can help activate the body's natural regenerative power to restore lost function. The company, which was incorporated in 2014, is currently at the clinical stage of its development and has a range of products in the pipeline. One such lead product candidate, FX-322, is already in Phase IIb clinical trials and shows promising potential to treat the root cause of sensorineural hearing loss. In addition, the company is exploring other therapeutic areas including degenerative diseases such as multiple sclerosis and conditions involving the muscle, GI tract, skin and bone. Frequency Therapeutics has partnered with leading institutions such as Massachusetts Eye and Ear, Massachusetts Institute of Technology, and The Scripps Research Institute, and also has a licensing and collaboration agreement with Astellas Pharma Inc. for the development and commercialization of FX-322.